Omicron hope Valneva: is the dead corona vaccine good as a booster or not?
Created: 12/19/2021, 9:44 PM
From: Jonas Raab
Valenva's corona vaccine is about to receive EU approval.
But what can the dead vaccine really do?
© Sven Simon / imago
The dead vaccine Valneva is very popular.
A study on the booster effect of the corona vaccine recently raised doubts about its suitability for approval.
The manufacturer holds against it.
Saint-Herblain - How Good is Valneva Really?
Many hopes are currently resting on the French dead vaccine and its supposed counterpart Novavax.
Both corona vaccines work on a different principle than Biontech, Moderna and Co. and are currently waiting for their EU approval.
They are particularly popular with people with reservations about the currently available mRNA and vector vaccines - although current studies have made people sit up and take notice.
One of these studies comes from the virus variant country Great Britain and especially scratched the savior image of Valneva's vaccine "VLA2001".
The study examined the booster effect of Valneva, Novavax, the now failed CureVac and the four previously approved vaccines Biontech, Johnson & Johnson, Moderna and AstraZeneca.
Dead vaccine Valneva in the study mess: is the vaccine suitable as a booster?
2900 people with a primary vaccination in Great Britain were given either one of the four approved vaccines, CureVac or Novavax or Valneva.
Moderna did the best, Valneva the least.
The new vaccine from France was the only booster vaccination that did not cause a significant boost in immunity.
The manufacturer is now holding against it with its own study.
Valneva explained the poor performance in the British study with the fact that the participants received the booster after a shorter interval than usual.
Inactivated vaccines, like Valneva's, usually take longer to take effect.
Corona: Vaccine manufacturer Valneva refers to its own booster study
Now Valneva announced, with reference to her own study, that his dead vaccine is very well suitable for third-party vaccination - provided that one can be vaccinated beforehand with the same vaccine. "The first results show an excellent immune response after the third dose of VLA2001 given 7 to 8 months after the second dose of the primary series," the company said on its website.
Valneva's Chief Medical Officer, Juan Carlos Jaramillo, commented, “We are very pleased to announce our initial booster data confirming that VLA2001 will maintain immunity in subjects who received VLA2001 as a primary vaccine regardless of the initial neutralizing antibody level at the time the refreshment, significantly increased. ”Jaramillo announced further studies that should prove the booster effect of the vaccine.
Valneva: This is how dead vaccines work - and that's what the EU says about them
In contrast to mRNA and vector vaccines, inactivated vaccines do not contain any viruses that can replicate. They consist of killed pathogens or pathogen components that can neither multiply nor trigger a disease. This method is used in the many vaccines against influenza and childhood diseases. The EU Commission recently described the procedure in the context of a sales contract as "proven" and "very safe".
Due to its proven mode of action, many people - especially or exclusively vaccine skeptics - are currently waiting for approval of a dead vaccine such as Valneva, but the head of the French biotech company thinks little of this attitude.
"I do not advise anyone to wait for our vaccine," said Thomas Lingelbach recently in the
mirror
.
"That would be ethically unacceptable."
Vaccine skeptics are waiting for dead vaccine against Corona: Valneva boss advises against it - "Hurry up"
According to Lingelbach, he recently had himself boosted with the mRNA product from Biontech.
It will probably be several weeks, if not months, before Valneva's own vaccine candidate is launched in the EU - and in view of the Omikron variant, speed is needed.
(yo)